Pfizer: Breast Neoplasms trials

The registry lists 182 Breast Neoplasms studies with Pfizer as lead sponsor. 6 are open to participants now and 101 have results posted.

Phase 1 50Phase 2 56Phase 3 25Phase 4 3No phase 61(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast CancerCompletedNCT00243503Phase 2Results posted
• Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast CancerCompletedNCT00143390Phase 3Results posted
• AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast CancerCompletedNCT00076024Phase 1/2Results posted
• Study Evaluating Temsirolimus (CCI-779) In Breast NeoplasmsCompletedNCT00062751Phase 2Results posted
• Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast CancerCompletedNCT00038467Phase 3Results posted
• Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On TamoxifenCompletedNCT00038103Phase 2Results posted
• Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By ExemestaneCompletedNCT00036270Phase 3Results posted
• A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060CompletedNCT07160738Phase 1
• A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese MarketCompletedNCT07096024
• A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast CancerActive, not recruitingNCT06966453Phase 1/2
• A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world DatabaseCompletedNCT06962969
• Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.CompletedNCT06961331
• Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingNCT06760637Phase 3
• A Study to Learn About the Safety of TALZENNA for the Treatment of Breast CancerActive, not recruitingNCT06735742
• A Study to Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in AustraliaCompletedNCT06624020
• A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerActive, not recruitingNCT06495164
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsActive, not recruitingNCT06157892Phase 2
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)TerminatedNCT06125522Phase 1/2
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingNCT06105632Phase 2
• A Study to Understand the Use of Palbociclib in Canadian Patients With Breast Cancer That Has Spread to Other OrgansCompletedNCT06003114
• A Study to Learn About the Relationship Between Hepatic Impairment and Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal-bow-sai-klib)CompletedNCT05912933
• Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerActive, not recruitingNCT05909397Phase 3
• Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.WithdrawnNCT05905341Phase 1
• A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in ChinaCompletedNCT05732428Phase 1
• A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)CompletedNCT05709158
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)TerminatedNCT05573555Phase 1/2
• TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)Active, not recruitingNCT05548127Phase 1/2
• Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBCCompletedNCT05505175
• A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data SettingCompletedNCT05478590
• Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in JapanCompletedNCT05399329
• Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Phase 1
• A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid TumorsActive, not recruitingNCT05262400Phase 1/2
• Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Phase 2
• Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South KoreaCompletedNCT05132101
• European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal TherapiesCompletedNCT05043506
• Korea Post Marketing Surveillance (PMS) Study of Talzenna®WithdrawnNCT04982848
• Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf RegionCompletedNCT04916509
• A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various CancerWithdrawnNCT04889495
• First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.Active, not recruitingNCT04767594
• Swedish Ibrance Registries Insights (SIRI)CompletedNCT04654208
• PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2
• TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.CompletedNCT04498481
• Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerApproved for marketingNCT04220203
• A Safety Study of SGN-CD47M in Patients With Solid TumorsTerminatedNCT03957096Phase 1
• Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®CompletedNCT03445637
• Expanded Access Use of Tucatinib for HER2+ Metastatic Breast CancerNo longer availableNCT03424473
• A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsTerminatedNCT02952989Phase 1
• Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast CancerWithdrawnNCT02929576Phase 3
• Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In TaiwanCompletedNCT02924584
• Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1
• Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast CancerCompletedNCT02270372Phase 1
• Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed AppropriateNo longer availableNCT02142868
• A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast CancerCompletedNCT02025192Phase 1
• A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast CancerCompletedNCT01983501Phase 1
• Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast CancerWithdrawnNCT01658176Phase 2
• Relative Bioavailability StudyCompletedNCT01602887Phase 1
• Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor TherapyCompletedNCT00784888
• Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy SubjectsCompletedNCT00777530Phase 1
• Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy SubjectsCompletedNCT00759837Phase 1
• Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast CancerWithdrawnNCT00678626Phase 2
• A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast CancerCompletedNCT00649090Phase 4
• CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By SurgeryWithdrawnNCT00635245Phase 1
• A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered TogetherCompletedNCT00618124Phase 1
• A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.WithdrawnNCT00471159Phase 2
• Effect of Bazedoxifene, Raloxifene, and Placebo on Breast DensityCompletedNCT00418236
• Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast CancerCompletedNCT00322517Phase 2
• Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast CancerCompletedNCT00279448Phase 3
• Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast CancerCompletedNCT00174434Phase 1
• Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer PatientsCompletedNCT00174343Phase 2
• MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.TerminatedNCT00147550Phase 1/2
• A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast CancerTerminatedNCT00102895Phase 2
• Study Evaluating MST-997 in Advanced Malignant Solid TumorsTerminatedNCT00088647Phase 1
• Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast CancerTerminatedNCT00083993Phase 3
• A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.CompletedNCT00078000Phase 2
• Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and CapecitabineCompletedNCT00072852Phase 2
• Study in Women With Metastatic Breast Cancer Whose Cancer Has Gotten Worse After Anthracycline and Taxane TherapyCompletedNCT00067314Phase 2
• A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast CancerCompletedNCT00051051Phase 2
• CPG 7909 Plus Herceptin® In Patients With Metastatic Breast CancerCompletedNCT00043394Phase 2
• PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)CompletedNCT00043368Phase 2
• Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal WomenTerminatedNCT00040014Phase 2
• A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic CancerCompletedNCT00034827Phase 2
• Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast CancerTerminatedNCT00028483Phase 2